<DOC>
	<DOCNO>NCT00465894</DOCNO>
	<brief_summary>The purpose study determine long act tolterodine confers benefit intravaginal low dose estrogen treatment Overactive Bladder Syndrome 12 week post-treatment initiation . The hypothesis low dose intra-vaginal estrogen confers great benefit tolterodine treatment Overactive Bladder symptom . Secondary outcome assess addition therapy treatment regimen confer benefit 24 week 52 week .</brief_summary>
	<brief_title>Detrol LA v Estrace Vaginal Cream Treatment Overactive Bladder Symptoms</brief_title>
	<detailed_description>Lower urinary tract bladder storage symptom include urinary frequency , urinary urgency , nocturia urge incontinence . Overactive Bladder ( OAB ) Syndrome condition urgency predominant symptom without urge incontinence usually accompany frequency nocturia . The mainstay treatment woman OAB syndrome treatment anticholinergic medication well behavioral therapy . This method treatment demonstrate 60 % response rate report Cochrane Database Systemic Reviews . In addition anticholinergic therapy , vaginal atrophy often correct part pharmacologic treatment plan . Vaginal atrophy condition vastly prevalent post-menopausal woman . It think affect 48 % post-menopausal woman . Many woman condition experience vaginal dryness , irritation , painful intercourse , well urinary symptom include dysuria , urgency , frequency , nocturia , incontinence recurrent urinary tract infection . Comparison : Tolterodine LA compare low dose intra-vaginal estrogen cream treatment OAB symptom</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Irritative voiding symptom include sensory urgency , frequency , urge incontinence , nocturia Postmenopausal woman prior oophorectomy 1 year last menstrual period Women age 4090 Women hysterectomy preserved ovary must age 55 great document FSH &gt; 40 ensure postmenopausal status Community dwell Ambulatory Ability participate 12 month study Postvoid residual volume &gt; 150ml Glaucoma without ophthalmologist clearance Hormone replacement therapy past 6 month Current anticholinergic treatment Breast cancer Impaired mental status Undiagnosed vaginal bleeding past 12 month Endometrial thickness pelvic ultrasound &gt; 5mm History thromboembolic event Gynecologic cancer Untreated urinary tract infection ( would eligible treatment ) Stage III pelvic organ prolapse great Recent diuretic medication change ( one month change ) Neurologic condition affect bladder function ( Multiple Sclerosis , Parkinsons , spinal cord injury , spina bifida ) Congestive heart failure Prior pelvic irradiation Interstitial cystitis</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>overactive bladder</keyword>
	<keyword>urge leakage</keyword>
	<keyword>nightime urination</keyword>
	<keyword>incontinence</keyword>
	<keyword>urinary frequency</keyword>
</DOC>